Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Skin Cancer

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

Clinical Applications of Epidermal Stem Cells

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...

Renewal of Skin Epidermal Stem Cells

Renewal of Skin Epidermal Stem Cells

The skin is divided into epidermis, dermis, and hypodermis, the skin's outermost, middle, and inner layers. The human epidermal layer regularly undergoes renewal, where old, dead cells are replaced by new cells. Epidermal stem cells or EpiSCs divide and differentiate to restore the lost cells. For the renewal process, some EpiSCs continuously self-renew. In contrast, few others differentiate into transit-amplifying cells, which later form prickle or spinous cells, followed by granular...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pathological fracture of primary lymphoma of bone: A case report on diagnosis and novel surgical management.

Oncology letters·2026

Same author

Multiscale mechanical heterogeneity and structural gradients in the annulus fibrosus-endplate interface in the spine characterized using AFM nanomechanical testing.

Journal of biomechanics·2026

Same author

Localization of dendritic cells and T cells within the tumor microenvironment in different types of skin cancer.

Histochemistry and cell biology·2026

Same author

A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia.

The New England journal of medicine·2026

Same author

Hypertrophic plaques in a patient with pulmonary adenocarcinoma.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026

Same author

Inclusion complex of fatty acids of pomegranate seed oil with betacyclodextrin: preparation, characterization and bioactivity.

Journal of food science and technology·2026

Search research articles

Related Experiment Video

Updated: Aug 2, 2025

Cell Population Analyses During Skin Carcinogenesis

Cell Population Analyses During Skin Carcinogenesis

Published on: August 21, 2013

New therapeutic developments for basal cell carcinoma.

Rainer Kunstfeld¹, Van Anh Nguyen²

¹University Hospital for Dermatology, Medical University Vienna, Vienna, Austria.

Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

|April 18, 2023

Summary

This summary is machine-generated.

Systemic therapy and immunotherapy are now approved treatments for advanced basal cell carcinoma (BCC). Future clinical trials will explore new drugs and combinations to further expand therapeutic options for locally advanced BCC and metastatic BCC.

More Related Videos

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression

Published on: August 3, 2011

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Related Experiment Videos

Last Updated: Aug 2, 2025

Cell Population Analyses During Skin Carcinogenesis

Cell Population Analyses During Skin Carcinogenesis

Published on: August 21, 2013

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression

Published on: August 3, 2011

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Area of Science:

Oncology
Dermatology

Background:

Systemic therapy for locally advanced basal cell carcinoma (laBCC) and metastatic basal cell carcinoma (mBCC) was introduced in 2013.
Immunotherapy has since been approved for treating these advanced forms of basal cell carcinoma.

Purpose of the Study:

To review the current landscape and future directions of systemic therapy and immunotherapy for advanced basal cell carcinoma.
To highlight the potential of emerging agents and combination regimens in expanding treatment options.

Main Methods:

Review of systemic therapy and immunotherapy approvals for laBCC and mBCC.
Analysis of ongoing clinical trials investigating novel agents and combination therapies.

Main Results:

Systemic therapy and immunotherapy represent significant advancements in treating advanced basal cell carcinoma.
Numerous novel agents and combination regimens are under investigation, showing promise for future treatment strategies.

Conclusions:

The therapeutic armamentarium for laBCC and mBCC has expanded significantly since 2013.
Ongoing research into new immunotherapies and drug combinations is expected to further improve outcomes for patients with advanced basal cell carcinoma.